FDA accepts NDA for pralatrexate, a treatment for peripheral T-cell lymphoma

Allos Therapeutics announced that the FDA has accepted for filing and granted priority review for the New Drug Application (NDA) submitted for pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).  The NDA is based on the results from the Company's Phase 2 trial known as PROPEL (Pralatrexate in patients with Relapsed or refractory PEripheral T-cell Lymphoma).  

Pralatrexate is a targeted antifolate designed to accumulate preferentially in cells expressing RFC-1, a protein that is over-expressed on certain cancer cells compared to normal cells.  

For more information please call (303) 426- 6262 or visit www.allos.com.